Dark

Check out our API

EVOTF
EVOTEC SE
stock OTC

Inactive

Jan 21, 2025

8.27USD-10.297%(-0.95)300

Pre-market

0.00USD-100.000%(-9.22)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 18, 2022

04:30AM EST Evotec and Lilly Entered into Drug Discovery Collaboration in Metabolic Diseases; Evotec to Receive Undisclosed Upfront Payment Plus Up to $1B in Milestone Payments and Royalties Benzinga

Jan 11, 2022

05:29AM EST Evotec Announced Expansion of Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach Benzinga

Oct 27, 2021

01:11PM EDT Germany Based Evotec Sets Terms For $576M US IPO Benzinga

Oct 11, 2021

08:34AM EDT Pasithea, Evotec Ink Drug Development Pact Benzinga

Oct 8, 2021

09:37AM EDT Evotec Expands Neuroscience Collaboration with Bristol Myers Benzinga

Sep 2, 2021

09:46AM EDT Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate Benzinga

Apr 19, 2021

05:17AM EDT Kazia Therapeutics Announced Worldwide Exclusive Licensing Deal & Master Services Deal With Evotec SE Benzinga

Mar 1, 2021

05:22AM EST Evotec, Chinook Therapeutics Ink Development Pact For Chronic Kidney Diseases Therapies Benzinga

Aug 20, 2020

06:13AM EDT CENTOGENE and Evotec Announced Expanded Collaboration Into Gaucher Disease Benzinga

Aug 18, 2020

05:28AM EDT Evotec and Novo Nordisk Form Strategic Alliance to Develop Novel Therapies for Kidney Diseases; Evotec tol Receive Undisclosed Upfront Payment, Research Funding and Milestone Potential of More Than 150M Per Product. Tiered Royalties on Net Sales Benzinga

Share